ATRC Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of -5.46% compared to AtriCure's net margin of -19.35%. AtriCure's return on equity of -8.3% beat iRhythm Technologies's return on equity of -112.03%.

AtriCure has a consensus price target of $49.89, signalling upside risk potential of 52.52%. On the other hand iRhythm Technologies has an analysts' consensus of $137.33 which suggests that it could fall by -2.6%. Given that AtriCure has higher upside potential than iRhythm Technologies, analysts believe AtriCure is more attractive than iRhythm Technologies.

AtriCure has a beta of 1.571, which suggesting that the stock is 57.127% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.343, suggesting its more volatile than the S&P 500 by 34.347%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

AtriCure quarterly revenues are $123.6M, which are smaller than iRhythm Technologies quarterly revenues of $158.7M. AtriCure's net income of -$6.7M is higher than iRhythm Technologies's net income of -$30.7M. Notably, AtriCure's price-to-earnings ratio is -- while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.21x versus 7.14x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of -5.46% compared to AtriCure's net margin of 30.99%. AtriCure's return on equity of -8.3% beat Intuitive Surgical's return on equity of 15.82%.

AtriCure has a consensus price target of $49.89, signalling upside risk potential of 52.52%. On the other hand Intuitive Surgical has an analysts' consensus of $573.63 which suggests that it could grow by 1.78%. Given that AtriCure has higher upside potential than Intuitive Surgical, analysts believe AtriCure is more attractive than Intuitive Surgical.

AtriCure has a beta of 1.571, which suggesting that the stock is 57.127% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

AtriCure quarterly revenues are $123.6M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. AtriCure's net income of -$6.7M is lower than Intuitive Surgical's net income of $698.4M. Notably, AtriCure's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 82.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.21x versus 23.48x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of -5.46% compared to AtriCure's net margin of -5.14%. AtriCure's return on equity of -8.3% beat Integer Holdings's return on equity of 4.85%.

AtriCure has a consensus price target of $49.89, signalling upside risk potential of 52.52%. On the other hand Integer Holdings has an analysts' consensus of $147.88 which suggests that it could grow by 22.22%. Given that AtriCure has higher upside potential than Integer Holdings, analysts believe AtriCure is more attractive than Integer Holdings.

AtriCure has a beta of 1.571, which suggesting that the stock is 57.127% more volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

AtriCure quarterly revenues are $123.6M, which are smaller than Integer Holdings quarterly revenues of $437.4M. AtriCure's net income of -$6.7M is higher than Integer Holdings's net income of -$22.5M. Notably, AtriCure's price-to-earnings ratio is -- while Integer Holdings's PE ratio is 57.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.21x versus 2.44x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular has a net margin of -5.46% compared to AtriCure's net margin of 18.39%. AtriCure's return on equity of -8.3% beat LeMaitre Vascular's return on equity of 13.74%.

AtriCure has a consensus price target of $49.89, signalling upside risk potential of 52.52%. On the other hand LeMaitre Vascular has an analysts' consensus of $104.50 which suggests that it could grow by 23.28%. Given that AtriCure has higher upside potential than LeMaitre Vascular, analysts believe AtriCure is more attractive than LeMaitre Vascular.

AtriCure has a beta of 1.571, which suggesting that the stock is 57.127% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.076%.

AtriCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular offers a yield of 0.85% to investors and pays a quarterly dividend of $0.20 per share. AtriCure pays -- of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

AtriCure quarterly revenues are $123.6M, which are larger than LeMaitre Vascular quarterly revenues of $59.9M. AtriCure's net income of -$6.7M is lower than LeMaitre Vascular's net income of $11M. Notably, AtriCure's price-to-earnings ratio is -- while LeMaitre Vascular's PE ratio is 42.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure is 3.21x versus 8.56x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.